Serotonin in Blood: Assessment of its Origin by Concomitant Determination of β-Thromboglobulin (platelets) and Chromogranin A (enterochromaffin cells) Abstract #612

Introduction: Serotonin is produced in enterochromaffin (EC) cells, taken up and stored in platelets and released during platelet activation. Measurement of platelet-poor plasma serotonin is difficult, mainly due to platelet activation during blood sampling.
Aim(s): To establish a method to assess the influence of platelet release upon platelet-poor plasma serotonin measurement by concomitant determination of serotonin, β-thromboglobulin (β-TG) and chromogranin A (CgA).
Materials and methods: Blood samples from patients with thrombocytosis, thrombocytopenia and small intestinal neuroendocrine (EC-cell) tumors (SI-NETs) as well as healthy volunteers were analyzed. We also measured serotonin in venous and arterial samples from patients undergoing coronary angiography to evaluate peripheral serotonin metabolism.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Øyvind Hauso

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1150 Platelet Serotonin But Not Dopamine Concentrations Are Lower in Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Patients Compared to Healthy Individuals.
Introduction: Platelets carry VEGF-A, serotonin and dopamine. Serotonin stimulates and dopamine inhibits tumor angiogenesis. We hypothesized that platelets are activated in tumor vasculature and release angiogenic factors, resulting in lower platelet serotonin and dopamine.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Marloes Peters
#1917 Clinical Correlates of Discrepant Results of Chromogranin a versus Serotonin Markers in Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors lead to elevated chromogranin A levels and elevated serotonin markers (urinary 5HIAA and platelet serotonin). These markers are employed for diagnosis and monitoring.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Wim Meijer
Authors: Meijer W, Bruikman C, Beukeveld G, ...
#2082 Evaluation of Everolimus (EVE) in Patients with Metastatic Lung Neuroendocrine Tumors
Introduction: Lung neuroendocrine tumors are rare, but their incidence has been steadily increasing in recent years.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment -Targeted therapies
Presenting Author: Anna Kuznetsova
#2213 Imaging Modality Depending on the Levels of Tumor Markers
Introduction: 18 F-Fluorodihydroxyphenylalanine(18F)-FDOPA positron emission tomography (PET)/computed tomography (CT) has the advantage of being a noninvasive test and is by far the most promising imaging modality for neuroendocrine tumors (NETs).
Conference: 15th Annual ENETS conference (2018)
Category: Imaging and Interventions (radiology, endoscopy)
Presenting Author: DOCTOR Julieta Iorio
Authors: Iorio J, Eleta M, Cuneo L, Polillo D, ...
#161 Low Dose Multiple Cycle (LD/MT) Peptide Receptor Radionuclide Therapy: a new concept for the treatment of well-differentiated metastatic neuroendocrine tumors
Introduction: It has been shown experimentally that low dose radiation can effectively kill slow growing cancer cells. Also, external beam radiation therapy applies a fractionated delivery of radiation dose to reduce toxicity with equal or even better therapeutic efficacy.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Vikas Prasad